Elliot Norry

Company: Adaptimmune

Job title: Chief Medical Officer

Seminars:

T-Cell Therapies in the Real World 9:00 am

Data supporting FDA approval of afamitresgene autoleucel, the first engineered T-cell therapy for solid tumors, targeting unresectable or metastatic synovial sarcoma Optimizing the regulatory process throughout development, and paving the way for future cell therapies Data from the IGNYTE ESO trial with letetresgene autoleucel for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS)Read more

day: Day 1

Industry Leaders’ Fireside Chat: A Commercial TCR-T & TCR Bispecific – What’s Next? 2:15 pm

• Reflecting on the past: celebrating the first TCR-T commercial approval and its impact on the field, along with novel clinical data • Determining the current state of play: discussing what challenges remain, the current funding environment and the priority for the field to outline present focus • What’s next? Discussing the potential for allogeneic…Read more

day: Day 1